Zealand Pharma A/S (Zealand Pharma A/S) FCF Margin % : 211.41% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Zealand Pharma A/S FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Zealand Pharma A/S's Free Cash Flow for the three months ended in Dec. 2023 was $7.19 Mil. Zealand Pharma A/S's Revenue for the three months ended in Dec. 2023 was $3.40 Mil. Therefore, Zealand Pharma A/S's FCF Margin % for the quarter that ended in Dec. 2023 was 211.41%.

As of today, Zealand Pharma A/S's current FCF Yield % is -1.20%.

The historical rank and industry rank for Zealand Pharma A/S's FCF Margin % or its related term are showing as below:

ZLDPF' s FCF Margin % Range Over the Past 10 Years
Min: -1225.63 Med: -290.77 Max: 16.59
Current: -131.67

During the past 13 years, the highest FCF Margin % of Zealand Pharma A/S was 16.59%. The lowest was -1225.63%. And the median was -290.77%.

ZLDPF's FCF Margin % is ranked better than
52.03% of 1036 companies
in the Biotechnology industry
Industry Median: -148.935 vs ZLDPF: -131.67

Zealand Pharma A/S FCF Margin % Historical Data

The historical data trend for Zealand Pharma A/S's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zealand Pharma A/S FCF Margin % Chart

Zealand Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,047.54

-371.75

-1,136.93

-917.43

-131.11

Zealand Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-1,166.10	-1,451.58	-1,714.46	-41.41	211.41

Competitive Comparison of Zealand Pharma A/S's FCF Margin %

For the Biotechnology subindustry, Zealand Pharma A/S's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma A/S's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma A/S's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Zealand Pharma A/S's FCF Margin % falls into.

Zealand Pharma A/S FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Zealand Pharma A/S's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-65.755	/	50.153
	=	-131.11 %

Zealand Pharma A/S's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	7.188	/	3.4
	=	211.41 %

Zealand Pharma A/S FCF Margin % Related Terms

Thank you for viewing the detailed overview of Zealand Pharma A/S's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zealand Pharma A/S (Zealand Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zealand Pharma A/S (OTCPK:ZLDPF) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

ZEALc:UK 0NZU:UK ZEAL:Denmark 22Z:Germany

Address

Sydmarken 11, Soborg, DNK, DK-2860

Website

https://www.zealandpharma.com

Zealand Pharma A/S is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.